Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in samples from

vaccinated individuals

Johannes Hayer[1]

Eva Urlaub[1]

[1]Roche Diagnostics GmbH, Mannheim, Germany

Corresponding author: Eva Urlaub, Roche Diagnostics GmbH, Mannheim, Germany,

eva.urlaub@roche.com

**Running title**

SARS-CoV-2 rapid POC antibody test in a vaccinated cohort

**Abstract (242/250)**

*Objective*

The study aimed to establish the performance of the SARS-CoV-2 Rapid Antibody

Test (IgG and IgM) and the Elecsys® Anti-SARS-CoV-2 S assay in vaccinated

individuals.

*Methods*

A panel of serum samples from Boca Biolistics was utilized to assess antibodies

following vaccination, consisting of samples drawn prior to vaccination, after the first

dose, or at least 14 days after the second dose of Moderna mRNA-1273 or Pfizer-

BioNTech BNT162b2 COVID-19 vaccines. Agreement between the two methods

was measured and stratified by test evaluator and assay lot.

*Results*

Agreement between the SARS-CoV-2 Rapid Antibody Test (IgG) and Elecsys Anti-

SARS-CoV-2 S assay qualitative measurements at the different assessment points

for both mRNA-1273 and BNT162b2 ranged between 97.06% (95% confidence

interval [CI] 84.67, 99.93) to 100% (95% CI 82.35, 100). Agreement of the SARS-

CoV-2 Rapid Antibody Test (IgG) with the Elecsys Anti-SARS-CoV-2 S assay was

not highly influenced by either lot or evaluator. There was a medium-to-strong

correlation between the semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG)

result and quantitative Elecsys Anti-SARS-CoV-2 S assay in samples taken after

both doses of the vaccines, with higher intensity bands being associated with higher

total anti-S antibody titer (mRNA-1273, $p=0.0019$; BNT162b2, $p<0.0001$).

*Conclusion*

Semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys

Anti-SARS-CoV-2 S assay correlated well, suggesting that the SARS-CoV-2 Rapid

Antibody Test (IgG) is helpful in understanding the immune response post-

vaccination. The current data support the use of the SARS-CoV-2 Rapid Antibody

Test (IgG) in the vaccinated population.

**Importance (148/150)**

Serologic assays are an essential tool for quality control of vaccines and to determine the response to vaccination. Although a correlate of immunity has not yet been established for COVID-19 vaccines, antibody titers after natural infection and vaccination have been associated with protection from symptomatic SARS-CoV-2 infection. Rapid point-of-care assays can potentially be of use in this context with advantages over centralized testing, such as speed and ease of use. The point-of-care SARS-CoV-2 Rapid Antibody Test (IgG) compared favorably to the Elecsys Anti-SARS-CoV-2 S assay with agreement rates above 97.06%, after one or two doses of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2. Semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-SARS-CoV-2 S assay results correlated well, suggesting that SARS-CoV-2 Rapid Antibody Test (IgG) is helpful in understanding the immune response post-vaccination. The current data support the use of the SARS-CoV-2 Rapid Antibody Test (IgG) in the vaccinated population.

**Keywords**

antibodies, neutralizing; COVID-19 vaccines; immunity; immunoassay; nucleocapsid protein; point-of-care systems; SARS-CoV-2; spike protein

## Introduction

Serologic immunoassays are vital in the global management of the COVID-19 pandemic. Measurement of antibodies to SARS-CoV-2 is important for improving disease management, and accurate tests, with validated sensitivity and specificity, are essential for obtaining reliable results when monitoring the pandemic (1). Serologic assays can provide evidence of recent or past infection (2), and identify those individuals still at risk of infection (3).

Infection with SARS-CoV-2 elicits a strong neutralizing antibody response (4), and antibodies that bind via the spike protein act as neutralizing antibodies (5, 6). Several studies have shown good correlation between anti-S antibodies and functional virus neutralization (7-11). Neutralization assays utilizing live virus require biosafety level 3 containment, which can be labor intensive and low throughput (12-14); therefore anti-S immunoassays, as a surrogate for neutralization, have an important role to play (13, 15). On an individual patient level, anti-S immunoassays can confirm vaccination status or inform upon the need for booster doses (16), which may be helpful for both social and medical reasons.

Moderna mRNA-1273 (spikevax™) and Pfizer-BioNTech BNT162b2 (COMIRNATY®) COVID-19 vaccines are mRNA vaccines, approved under the U.S. Food and Drug Administration's emergency use authorization, each employing a two-dose regimen (17, 18). The immune response involves B cells that produce binding and neutralizing antibodies against the SARS-CoV-2 S protein (19, 20) and both vaccines encode the SARS-CoV-2 spike protein to generate an immune response. Serologic assays are an essential tool in vaccine quality control, being used to determine the response to vaccination and providing insight into the antibody response from the individual patient perspective (21, 22).

The Elecsys® Anti-SARS-CoV-2 S assay (Roche Diagnostics International Ltd,

Rotkreuz, Switzerland) is an electrochemiluminescence immunoassay (ECLIA),

which has been developed for quantitative *in vitro* detection of antibodies in human

serum and plasma (23). The assay detects total antibodies, including

immunoglobulin G (IgG), against the receptor binding domain (RBD) of the SARS-

CoV-2 spike protein, and is intended for use on the fully automated and high-

throughput cobas e analyzers (23). The assay has been shown to detect anti-S

antibodies across a variety of different populations (2, 24), and has been utilized as a

surrogate of neutralization activity (11, 25).

The SARS-CoV-2 Rapid Antibody Test (Roche Diagnostics International Ltd,

Rotkreuz, Switzerland) is CE-marked rapid chromatographic immunoassay intended

for the qualitative *in vitro* detection of both IgM and IgG antibodies to SARS-CoV-2

spike or nucleocapsid proteins in human serum, plasma or whole blood, for

professional use in the laboratory and at point-of-care (26). A study utilizing real-

world clinical samples in unvaccinated individuals demonstrated that the SARS-CoV-

2 Rapid Antibody Test had comparable performance with the Elecsys Anti-SARS-

CoV-2 assay that targets the nucleocapsid protein (27).

The objective of this study was to establish the performance of the SARS-CoV-2

Rapid Antibody Test and the Elecsys Anti-SARS-CoV-2 S assay in serum samples

obtained from individuals who had received a COVID-19 vaccination.

**Materials and Methods**

*Study design*

The study was a retrospective performance study conducted at Roche Diagnostics

GmbH (Mannheim, Germany). All samples were analyzed with the SARS-CoV-2

Rapid Antibody Test and compared with the Elecsys Anti-SARS-CoV-2 S assay.

Tests were conducted as per manufacturer's instructions (23).

*Samples*

To assess antibodies following vaccination, a post-vaccination panel was prepared

using 75 serum samples obtained from Boca Biolistics (Florida, USA), collected

between February and April 2021, and stored at -20°C or colder (all available

samples at the time of request). Serum samples were from individuals from the USA

sampled prior to vaccination, after the first dose, or at least 14 days after the second

dose of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2 (Supplemental Table

1).

Samples were separated into aliquots of 50 µL for the SARS-CoV-2 Rapid Antibody

Test measurement and 200 µL for the Elecsys Anti-SARS-CoV-2 S reference

measurement on the cobas® 6000 and stored at -80°C until use.

An in-house panel of 15 negative serum samples, previously determined negative by

Elecsys Anti-SARS-CoV-2 S assay, was utilized to assess the specificity of the

SARS-CoV-2 Rapid Antibody Test. Samples were collected in June 2021 as part of

an in-house blood donation service at Roche Diagnostics (Mannheim, Germany),

anonymized, and stored at -80°C until use. No information about vaccination status

was available. Evaluators were blinded as to the origin of the samples.

*SARS-CoV-2 Rapid Antibody Test*

The SARS-CoV-2 Rapid Antibody Test detects the presence of SARS-CoV-2 IgM

and IgG antibodies, and the intensity of the test line is dependent upon the level of

SARS-CoV-2 antibodies present in the sample (26). In unvaccinated individuals, the

reported sensitivity is 92.59% (7–14 days post-symptom onset [POS]) and 99.03%

(>14 days POS), with specificity of 98.65% (26).

Each sample was tested with two different lots of the SARS-CoV-2 Rapid Antibody

Test. The readout was visually assessed at 10 minutes by two different independent

evaluators; these evaluators were not the operators who had performed the test. In

accordance with manufacturer's instructions, the sample was considered positive if

the control line and at least one colored band/test line at G or M became apparent

(qualitative determination). As an exploratory analysis, results were further defined

by the intensity of the band to provide semi-quantitative data (Supplemental Table

2). Data are presented separated by lot and by evaluator. In the event of an invalid

result, the test would be repeated.

*Elecsys Anti-SARS-CoV-2 S assay*

The Elecsys Anti-SARS-CoV-2 S assay results are reported automatically as the

analyte concentration of each sample in U/mL, with <0.80 U/mL interpreted as

negative and ≥0.80 U/mL interpreted as positive for anti-SARS-CoV-2 S antibodies

(23). The reported sensitivity and specificity of this test 14 days post-PCR is 97.92%

and 99.95%, respectively (24). The quantification range is between 0.4 and 250

U/mL and the reported limit of detection is 0.35 U/mL (23). If the sample

concentration is >250 U/mL, the sample can be diluted up to 1:100; in these cases,

the final result is determined as >25,000 U/mL (23).

In the event of an invalid result, the test would be repeated. All samples were

measured in duplicate, and the result calculated as the arithmetic mean of both

replicates. Assessors were blinded to the SARS-CoV-2 Rapid Antibody Test results

and blinded as to the origin of the samples.

     *Statistical analysis*

The agreement rates comparing the SARS-CoV-2 Rapid Antibody Test with Elecsys

Anti-SARS-CoV-2 S assay per vaccine type were calculated per lot. Two-sided 95%

Clopper–Pearson confidence intervals (CI) for the agreement rates are given.

Correlation between the semi-quantitative SARS-CoV-2 Rapid Antibody Test data

and quantitative Elecsys Anti-SARS-CoV-2 S assay data was assessed using the

Kendall's rank correlation τ. Accuracy of the SARS-CoV-2 Rapid Antibody Test result

— how often do the qualitative results agree with one another — was assessed by

lot and evaluator. Statistical analyses were conducted using R (version 3.6.3) and

JMP (version 15).

**Results**

Overall, the study cohort consisted of 56 predominantly white/Caucasian individuals

(median age 70 years; 55.36% female) with a variety of pre-existing medical

conditions (Table 1). No invalid results were generated using either test.

*Analyses of the SARS-CoV-2 Rapid Antibody Test (qualitative) with the Elecsys Anti-*

*SARS-CoV-2 S assay (quantitative and qualitative)*

Eight samples were obtained from patients who were sampled prior to vaccination.

Whilst only two patients were reported to have been previously diagnosed with

COVID-19, only one patient was IgG and IgM negative (by both the SARS-CoV-2

Rapid Antibody Test and Elecsys Anti-SARS-CoV-2 S assay). For the seven positive

samples, Elecsys Anti-SARS-CoV-2 S total antibody titers ranged from 254.0 U/mL

to >25,000 U/mL and all were identified as positive by the SARS-CoV-2 Rapid

Antibody Test.

The post-vaccination antibody analysis included 25 samples from individuals

vaccinated with mRNA-1273 and 42 vaccinated with BNT162b2. The dosing interval

between first and second vaccine doses for BNT162b2 was a median of 21 days

(minimum 19 days, maximum 23 days) and a median of 28 days (minimum 21 days,

maximum 32 days) for mRNA-1273. There was good agreement between the SARS-

CoV-2 Rapid Antibody Test (IgG) and Elecsys Anti-SARS-CoV-2 S qualitative

measurements at the different assessment points for both the Moderna and Pfizer-

BioNTech vaccines ranging from 97.06% (95% CI 84.67, 99.93) to 100% (95% CI

89.72, 100) (Table 2). There was one false-negative sample with evaluator 2 (after

second dose of BNT162b2, lot 1 and lot 2), however this sample was classified as

positive by evaluator 1.

There was poor agreement between the SARS-CoV-2 Rapid Antibody Test (IgM)

and Elecsys Anti-SARS-CoV-2 S assay qualitative measurements at the different

assessment points for both BNT162b2 and mRNA-1273 ranging from 14.71% (95%

CI 4.95, 31.06) to 83.33% (95% CI 35.88, 99.58) with many false-negatives (Table

2).

Using the in-house negative panel, there were no false-positive results for either lot

or evaluator (Supplemental Table 3).

*Analyses of the SARS-CoV-2 Rapid Antibody Test (semi-quantitative) with the*

*Elecsys Anti-SARS-CoV-2 S assay (quantitative)*

There was a medium-to-strong correlation between the semi-quantitative SARS-

CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-SARS-CoV-2 S

assay in samples taken after both doses of the vaccines (Figure 1), with higher

intensity bands being associated with higher total anti-S antibody titer (with Kendall's

τ up to 0.599 for IgG mRNA-1273 [p=0.0019] and 0.6833 [p<0.0001] for IgG

BNT162b2) (Supplemental Table 4). There was no correlation between the

quantitative Elecsys Anti-SARS-CoV-2 S assay result and the intensity of the SARS-

CoV-2 Rapid Antibody Test (IgM) (Supplemental Table 4).

Agreement between the semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgM)

and quantitative Elecsys Anti-SARS-CoV-2 S assay was poor, with many samples

designated as negative on the SARS-CoV-2 Rapid Antibody Test (IgM) even in the

presence of high anti-S antibody titers (Figure 2).

*Accuracy of the SARS-CoV-2 Rapid Antibody Test*

Comparison of the SARS-CoV-2 Rapid Antibody Test (IgG) results by lot or

evaluator revealed that these factors did not influence the results, with a minimum

accuracy estimate of 97.06% (Supplemental Figure 1).

SARS-CoV-2 Rapid Antibody Test (IgM) positivity appeared to be influenced by

evaluator, with a minimum accuracy estimate of 50% and considerable variability in

accuracy estimates across the different time points and vaccines (Supplemental

Figure 2).

*Evaluation of Elecsys Anti-SARS-CoV-2 S assay titer post-vaccination*

Antibody titers by days following final vaccination are shown in Figure 3. Following

complete vaccination with BNT162b2 or mRNA-1273 and up to approximately 20

days, there was significant variability with both high (maximum >25,000 U/mL) and

low (minimum 238.2 U/mL for BNT162b2 and 340.2 U/mL for mRNA-1273) anti-S

titers. After 30 days, anti-S titers for both vaccines commonly declined to below

5,000 U/mL (overall minimum 13.53 U/mL 25 days after vaccination with BNT162b2).

The median time between final vaccination and final measurement for those

vaccinated with BNT162b2 was 18 days (minimum 14 days, maximum 44 days) and

46 days (minimum 14 days, maximum 65 days) for mRNA-1273. Anti-S antibody

titers were numerically higher in participants vaccinated mRNA-1273 (median 2,307

U/mL; interquartile range [IQR] 872–6,845) than in those who received BNT162b2

(median 1,601 U/mL; IQR 467–3,131).

*Longitudinal analysis*

A small number of individuals had samples available from all three time points

(BNT162b2 cohort), allowing longitudinal evaluation of anti-S antibody titer levels; all

except one showed high levels of anti-S antibody titers at the first time point (prior to

vaccination). There was considerable variance in the effect of vaccination upon anti-

S antibody titers, however the greatest change was for the individual who was

infection-naïve (<0.4 U/mL to 1,645 U/mL following the second dose). For four

individuals, anti-S antibody titers actually decreased over time despite vaccination

with BNT162b2 (Supplemental Figure 3).

**Discussion**

Serologic assays are an essential tool for quality control of vaccines and to

determine the response to vaccination. Although a correlate of immunity has not yet

been established for COVID-19 vaccines, antibody titers after natural infection and

vaccination have been associated with protection from symptomatic SARS-CoV-2

infection (28); and rapid point-of-care assays can potentially be of use in this setting

with particular advantages over centralized testing, such as speed and ease of use.

We evaluated the use of the SARS-CoV-2 Rapid Antibody Test in vaccinated

individuals in comparison with the Elecsys Anti-SARS-CoV-2 S assay.

Our results indicate that the Elecsys Anti-SARS-CoV-2 S assay detects anti-S

antibodies after the first dose of both BNT162b2 and mRNA-1273, in agreement with

previous studies of the adaptive humoral response to vaccination in various

populations (21, 22, 29-33).

Whilst the performance of rapid antibody tests has been reported in unvaccinated

individuals (34-36), no studies have yet reported upon their use in vaccinated

individuals. The SARS-CoV-2 Rapid Antibody Test (IgG) compared favorably to the

Elecsys Anti-SARS-CoV-2 S assay with agreement rates above 97.06%, after one

dose and two doses, similar to what has been observed in unvaccinated individuals

(27). Assessment of the influence of lot or evaluator revealed that agreement of the

SARS-CoV-2 Rapid Antibody Test (IgG) with the Elecsys Anti-SARS-CoV-2 S assay

was not highly influenced by either factor, suggesting that the SARS-CoV-2 Rapid

Antibody Test (IgG) is robust under normal usage conditions.

There was low agreement of the SARS-CoV-2 Rapid Antibody Test (IgM) with the

Elecsys Anti-SARS-CoV-2 S assay because, in general, there is a lower sensitivity

for IgM compared with IgG for point-of-care lateral flow assays, as exemplified in a

recent analysis of healthcare workers vaccinated with the first dose of the Pfizer

vaccine and sampled 21–24 days thereafter (37). In addition, the Elecsys Anti-

SARS-CoV-2 S assay preferentially detects high-affinity IgG antibodies that compete

with IgM antibodies (23), contributing to the lower agreement rates with IgM results.

The vaccines were administered in accordance with the relevant primary dosing

schedules, with approximately 3 weeks for BNT162b2 and 1 month for mRNA-1273

between doses (17, 18). Whilst the data reported herein suggest some variation in

the level of antibody titers afforded by the vaccines, two doses of either mRNA-1273

or BNT162b2 induced high levels of anti-S antibodies. Anti-S total antibody titers

were higher in participants vaccinated with mRNA-1273 than BNT162b2, in

accordance with previous publications (38). Whilst the clinical significance of

quantitative differences in antibody titers following COVID-19 vaccination have not

yet been established, understanding the differences in antibody titer can support

individual choices and assist with policy decisions.

Seven individuals in the BNT162b2 cohort appeared to have previously undiagnosed

SARS-CoV-2 infection prior to vaccination and the effect of vaccination upon anti-S

antibody titers in this group at the individual level was highly variable (relative

decrease or increase). Overall, after primary vaccination with two doses, all except

one of those with previous natural infection had higher anti-S antibody titers than the

infection-naïve participant, in agreement with previous reports which support higher

titers following vaccination in previously infected individuals (38-40).

The findings of this study are subject to several limitations. The performance of the

SARS-CoV-2 Rapid Antibody Test in vaccinated individuals was based on the

evaluation of a relatively small panel of samples and utilized only two vaccines.

However, the cohort tested was generally representative of an aged US population,

with hypertension and diabetes mellitus in line with age-related expectations of

prevalence (41, 42).

The clinical relevance of semi-quantitative results is currently unknown and, at

present, cannot be interpreted as an indication of varying levels of immunity.

However, semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative

Elecsys Anti-SARS-CoV-2 S assay results correlated well, suggesting that SARS-

CoV-2 Rapid Antibody Test (IgG) is helpful in understanding the immune response

post-vaccination. The current data support the use of the SARS-CoV-2 Rapid

Antibody Test (IgG) into the vaccinated population.

**Conflicts of interest**

All authors have completed the ICMJE uniform disclosure form at

[www.icmje.org/coi_disclosure.pdf](www.icmje.org/coi_disclosure.pdf) and declare: that JH and EU are employees of

Roche Diagnostics; EU participates in Roche Connect; no other relationships or

activities that could appear to have influenced the submitted work.

**Ethical approval and consent**

Anonymized samples were provided by the commercial supplier Boca Biolistics and

collected under their ethical approval system. Ethical approval for the in-house panel

was provided by Ethik-Kommission II der Universität Heidelberg, Medizinische

Fakultät, Mannheim, Germany. Samples were anonymized, and collected and tested

in accordance with applicable regulations, including relevant European Union

directives and regulations, and the principles of the Declaration of Helsinki.

**Data availability**

Qualified researchers may request access to individual anonymized patient-level

data through the clinical study data request platform (https://vivli.org/). Further details

on Roche's criteria for eligible studies are available here:

https://vivli.org/members/ourmembers/. For further details on Roche's Global Policy

on the Sharing of Clinical Information and how to request access to related clinical

study documents, see here:

https://www.roche.com/research_and_development/who_we_are_how_we_work/clin

ical_trials/our_commitment_to_data_sharing.htm.

**Funding**

Roche Diagnostics GmbH (Mannheim, Germany) provided financial support for the study and for preparation of the article. Roche Diagnostics GmbH was involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. Medical writing support was funded by Roche Diagnostics GmbH.

**Acknowledgements**

Medical writing support was provided by Corrinne Segal, Elements Communications Ltd, Westerham, UK. The authors would like to thank Rabea Held, Regina Draude, Maureen Adamietz, Shervan Horo, and Jlenia Marconi of Roche Diagnostics for their contribution to the study. COBAS, COBAS E, and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners'. The specific application (use in vaccinated individuals) is currently outside of the intended use of the SARS-CoV-2 Rapid Antibody Test. The Elecsys Anti-SARS-CoV-2 S assay is approved under an Emergency Use Authorization in the US.

## References

**References**

1.  Krammer F, Simon V. 2020. Serology assays to manage COVID-19. Science
368:1060–1061.

2.  Riester E, Majchrzak M, Mühlbacher A, Tinguely C, Findeisen P, Hegel JK,
Laimighofer M, Rank CM, Schönfeld K, Langen F, Laengin T, Niederhauser C.
2021. Multicentre performance evaluation of the Elecsys Anti-SARS-CoV-2
immunoassay as an aid in determining previous exposure to SARS-CoV-2. Infect
Dis Ther doi:10.1007/s40121-021-00504-9:1–17.

3.  Alter G, Seder R. 2020. The power of antibody-based surveillance. N Engl J Med
383:1782–1784.

4.  Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, Ko RLW,
Chan KH, Cheng SMS, Perera R, Cowling BJ, Poon LLM, Peiris M. 2021.
Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 12:63.

5.  Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, Derclaye S,
Vincent SP, Soumillion P, Alsteens D. 2020. Molecular interaction and inhibition
of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun 11:4541.

6.  Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. 2020. Structural basis for the
recognition of SARS-CoV-2 by full-length human ACE2. Science 367:1444–1448.

7.  Bal A, Pozzetto B, Trabaud MA, Escuret V, Rabilloud M, Langlois-Jacques C,
Paul A, Guibert N, D'Aubarède-Frieh C, Massardier-Pilonchery A, Fabien N,
Goncalves D, Boibieux A, Morfin-Sherpa F, Pitiot V, Gueyffier F, Lina B, Fassier
JB, Trouillet-Assant S. 2021. Evaluation of high-throughput SARS-CoV-2

serological assays in a longitudinal cohort of patients with mild COVID-19: clinical

sensitivity, specificity, and association with virus neutralization test. Clin Chem

67:742–752.

8.    Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, Blocki FA,

Pallavicini L, Chinali A, Campisi D, Percivalle E, DiNapoli AP, Perno CF, Baldanti

F. 2020. Clinical and analytical performance of an automated serological test that

identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively. J Clin

Microbiol 58:e01224–20.

9.    Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, McGuire

J, Clearly S, Furrie E, Greig N, Hay G, Templeton K, Lorenzi JCC, Hatziioannou

T, Jenks S, Bieniasz PD. 2021. Longitudinal serological analysis and neutralizing

antibody levels in coronavirus disease 2019 convalescent patients. J Infect Dis

223:389–398.

10.    Weidner L, Gänsdorfer S, Unterweger S, Weseslindtner L, Drexler C, Farcet M,

Witt V, Schistal E, Schlenke P, Kreil TR, Jungbauer C. 2020. Quantification of

SARS-CoV-2 antibodies with eight commercially available immunoassays. J Clin

Virol 129:104540.

11.    Rubio-Acero R, Castelletti N, Fingerle V, Olbrich L, Bakuli A, Wölfel R, Girl P,

Müller K, Jochum S, Strobl M, Hoelscher M, Wieser A. 2021. In search of the

SARS-CoV-2 protection correlate: Head-to-head comparison of two quantitative

S1 assays in pre-characterized oligo-/asymptomatic patients. Infect Dis Ther

10:1505–1518.

12.    Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M, Lu Q,

385           Li X, Sun Q, Liu J, Fan C, Huang W, Xu M, Wang Y. 2020. Establishment and

386           validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg

387           Microbes Infect 9:680–686.

388    13.    Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS,

389           Carmichael JC, Chiu HP, Azarm KD, Haas GD, Amanat F, Klingler J, Baine I,

390           Arinsburg S, Bandres JC, Siddiquey MNA, Schilke RM, Woolard MD, Zhang H,

391           Duty AJ, Kraus TA, Moran TM, Tortorella D, Lim JK, Gamarnik AV, Hioe CE,

392           Zolla-Pazner S, Ivanov SS, Kamil JP, Krammer F, Lee B. 2021. Quantifying

393           absolute neutralization titers against SARS-CoV-2 by standardized virus

394           neutralization assay allows for cross-cohort comparisons of COVID-19 sera.

395           mBio 12:e02492–20.

396    14.    Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E,

397           Rouphael N, Edupuganti S, Shi PY, Menachery VD, Wrammert J, Suthar MS.

398           2020. Development of a rapid focus reduction neutralization test assay for

399           measuring SARS-CoV-2 neutralizing antibodies. Curr Protoc Immunol 131:e116.

400    15.    Jochum S, Kirste I, Hortsch S, Grunert VP, Legault H, Eichenlaub U, Kashlan B,

401           Pajon R. 2021. Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19

402           vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial. medRxiv

403           doi:10.1101/2021.10.04.21264521:2021.10.04.21264521.

404    16.    Baldanti F, Ganguly N, Wang G, Möckel M, O'Neill L, Renz H, Eduardo dos

405           Santos Ferreira C, Tateda K, Van Der Pol B. 2021. Deployment of SARS-CoV-2

diagnostic testing: challenges and key considerations for the future. Clin Rev Lab

Sci [submitted].

17.  Pfizer-BioNTech. 2021.  Fact sheet for healthcare providers administering

vaccine (vaccination providers): emergency use authorization (EUA) of the

Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019

(COVID-19). https://www.fda.gov/media/153713/download. Accessed 26 Nov

2021.

18.  Moderna TX. 2021.  Fact sheet for healthcare providers administering vaccine

(vaccination providers): emergency use authorization (EUA) of the moderna

COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19).

https://www.fda.gov/media/144637/download. Accessed 26 Nov 2021.

19.  Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M,

Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B,

Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B,

Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W,

Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH. 2021. Durability

of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med 384:80–

82.

20.  Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Hofer P,

Perkmann T, Haslacher H, Thalhammer R, Winkler S, Blüml S, Stiasny K, Aberle

JH, Smolen JS, Heinz LX, Aletaha D, Bonelli M. 2021. SARS-CoV-2 vaccination

in rituximab-treated patients: B cells promote humoral immune responses in the

presence of T-cell-mediated immunity. Ann Rheum Dis 80:1345–1350.

21.    Lukaszuk K, Kiewisz J, Rozanska K, Dabrowska M, Podolak A, Jakiel G,

Woclawek-Potocka I, Lukaszuk A, Rabalski L. 2021. Usefulness of IVD kits for

the assessment of SARS-CoV-2 antibodies to evaluate the humoral response to

vaccination. Vaccines 9:840.

22.    Salvagno GL, Henry BM, di Piazza G, Pighi L, De Nitto S, Bragantini D,

Gianfilippi GL, Lippi G. 2021. Anti-SARS-CoV-2 receptor-binding domain total

antibodies response in seropositive and seronegative healthcare workers

undergoing COVID-19 mRNA BNT162b2 Vaccination. Diagnostics 11:832.

23.    Roche Diagnostics. 2021. Elecsys® Anti-SARS-CoV-2 S, instructions for use

(09289275190, V3.0, Dec 2021).

24.    Riester E, Findeisen P, Hegel JK, Kabesch M, Ambrosch A, Rank CM, Pessl F,

Laengin T, Niederhauser C. 2021. Performance evaluation of the Roche Elecsys

Anti-SARS-CoV-2 S immunoassay. J Virol Methods 297:114271.

25.    Resman Rus K, Korva M, Knap N, Avšič Županc T, Poljak M. 2021. Performance

of the rapid high-throughput automated electrochemiluminescence immunoassay

targeting total antibodies to the SARS-CoV-2 spike protein receptor binding

domain in comparison to the neutralization assay. J Clin Virol 139:104820.

26.    Roche Diagnostics/SD BioSensor. 2020. SARS-CoV-2 Rapid Antibody Test,

instructions for use (9901-NCOV-02C, V2.0, Sept 2020).

27.    Findeisen P, Stiegler H, Lopez-Calle E, Schneider T, Urlaub E, Hayer J,

Zemmrich C. 2021. Clinical performance evaluation of a SARS-CoV-2 Rapid

Antibody Test for determining past exposure to SARS-CoV-2. Int J Infect Dis

103:636–641.

28.  Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao

K, Kent SJ, Triccas JA, Davenport MP. 2021. Neutralizing antibody levels are

highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

Nat Med 27:1205–1211.

29.  Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice

R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb

CA, Macdonald J, Mehta S, Pollok RC, Raine T, Smith PJ, Verma AM, Jochum

S, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T. 2021. Infliximab is

associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-

19 SARS-CoV-2 vaccines in patients with IBD. Gut 70:1884–1893.

30.  Callegaro A, Borleri D, Farina C, Napolitano G, Valenti D, Rizzi M, Maggiolo F.

2021. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in

subjects with previous SARS-CoV-2 infection. J Med Virol 93:4612–4615.

31.  Cavalcanti E, Isgrò MA, Rea D, Di Capua L, Trillò G, Russo L, Botti G, Miscio L,

Buonaguro FM, Bianchi AAM. 2021. Vaccination strategy and anti - SARS-CoV-

2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer

Center (Naples, Italy). Infect Agent Cancer 16:32.

32.  Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales M, Ziv T,

Shorer Arbel Y, Scarfò L, Joffe E, Perry C, Ghia P. 2021. Efficacy of the

BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic

leukemia. Blood 137:3165–3173.

33.   Seyahi E, Bakhdiyarli G, Oztas M, Kuskucu MA, Tok Y, Sut N, Ozcifci G,

Ozcaglayan A, Balkan, II, Saltoglu N, Tabak F, Hamuryudan V. 2021. Antibody

response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated

diseases: a controlled study among hospital workers and elderly. Rheumatol Int

41:1429–1440.

34.   Batra R, Olivieri LG, Rubin D, Vallari A, Pearce S, Olivo A, Prostko J, Nebbia G,

Douthwaite S, Rodgers M, Cloherty G. 2020. A comparative evaluation between

the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™

SARS CoV-2 IgG assay. J Clin Virol 132:104645.

35.   Naranbhai V, Chang CC, Beltran WFG, Miller TE, Astudillo MG, Villalba JA, Yang

D, Gelfand J, Bernstein BE, Feldman J, Hauser BM, Caradonna TM, Alter G,

Murali MR, Jasrasaria R, Quinlan J, Xerras DC, Betancourt JR, Louis DN,

Schmidt AG, Lennerz J, Poznansky MC, Iafrate AJ. 2020. High seroprevalence

of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts. J Infect Dis

222:1955–1959.

36.   Pallett SJC, Rayment M, Patel A, Fitzgerald-Smith SAM, Denny SJ, Charani E,

Mai AL, Gilmour KC, Hatcher J, Scott C, Randell P, Mughal N, Jones R, Moore

LSP, Davies GW. 2020. Point-of-care serological assays for delayed SARS-CoV-

2 case identification among health-care workers in the UK: A prospective

multicentre cohort study. Lancet Respir Med 8:885–894.

37.　Saluzzo F, Mantegani P, Poletti De Chaurand V, Quaresima V, Cugnata F, Di

Serio C, Macé A, De Vos M, Sacks JA, Cirillo DM. 2021. SARS-CoV-2 Antibody

Rapid Tests: Valuable Epidemiological Tools in Challenging Settings. Microbiol

Spectr 9:e0025021.

38.　Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. 2021. Comparison of

SARS-CoV-2 antibody response following vaccination with BNT162b2 and

mRNA-1273. JAMA 326:1533–1535.

39.　Di Meo A, Miller JJ, Fabros A, Brinc D, Hall V, Pinzon N, Ierullo M, Ku T, Ferreira

VH, Kumar D, Pasic MD, Kulasingam V. 2021. Evaluation of three anti-SARS-

CoV-2 serologic immunoassays for post-vaccine response. J Appl Lab Med Aug

3:jfab087.

40.　Terpos E, Trougakos IP, Karalis V, Ntanasis-Stathopoulos I, Gumeni S,

Apostolakou F, Sklirou AD, Gavriatopoulou M, Skourti S, Kastritis E, Korompoki

E, Papassotiriou I, Dimopoulos MA. 2021. Kinetics of anti-SARS-CoV-2 antibody

responses 3 months post complete vaccination with BNT162b2; A prospective

study in 283 health workers. Cells 10:1942.

41.　Centers for Disease Control and Prevention. 2020.  National diabetes statistic

report, 2020. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-

statistics-report.pdf. Accessed 24 Nov 2021.

42.　Ostchega R, Fyar C, Nwanko T, Nguyen D. 2020. Hypertension prevalence

among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief

364:1–8.

 **Tables and figures for ms**

 Table 1: Demographics of the donors from the Boca Biolistics panel

| Characteristics | All<br><br>N=56 | Pfizer<br><br>n=34 | Moderna<br><br>n=22 |
|---|---|---|---|
| **Male/female, %** | 44.64/55.36 | 44.12/55.88 | 45.45/54.55 |
| **Median age, IQR** | 70 (61.75–72) | 70 (63–71.75) | 71 (57.25–73) |
| **Ethnicity, %** | | | |
| Asian; Not Hispanic/Latino, | 1.79 | 2.94 | 0 |
| Black/African American; Not Hispanic/Latino | 3.57 | 5.88 | 0 |
| White/Caucasian; Not Hispanic/Latino | 64.29 | 61.76 | 68.18 |
| Hispanic/Latino; Black/African American | 7.14 | 8.82 | 4.55 |
| Hispanic/Latino; White/Caucasian | 23.21 | 20.59 | 27.27 |
| **Pre-existing medical conditions, %** | | | |
| Yes/No | 51.79/48.21 | 50.00/50.00 | 54.55/45.45 |
| Hypertension, Yes/No | 60.71/39.29 | 35.29/64.71 | 54.55/45.45 |

| | | | |
|---|---|---|---|
| Diabetes mellitus, Yes/No | 7.14/92.86 | 11.76/88.24 | 0/100 |

518    IQR, interquartile range

Table 2: Agreement between SARS-CoV-2 Rapid Antibody Test (IgG and IgM) and Elecsys Anti-SARS-CoV-2 S assay (reference test) qualitative measurements as measured by lot and evaluator using the Boca Biolistics donor panel, and after one dose or at least 14 days after two doses of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2

|  |  | mRNA-1273 | | | | | | | | BNT162b2 | | | | | | | |
|  |  | 1 dose | | | | 2 doses | | | | 1 dose | | | | 2 doses | | | |
|  |  | Evaluator 1 | | Evaluator 2 | | Evaluator 1 | | Evaluator 2 | | Evaluator 1 | | Evaluator 2 | | Evaluator 1 | | Evaluator 2 | |
|  |  | Lot 1 | Lot 2 | Lot 1 | Lot 2 | Lot 1 | Lot 2 | Lot 1 | Lot 2 | Lot 1 | Lot 2 | Lot 1 | Lot 2 | Lot 1 | Lot 2 | Lot 1 | Lot 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ig G | N | 6 | 6 | 6 | 6 | 19 | 19 | 19 | 19 | 8 | 8 | 8 | 8 | 34 | 34 | 34 | 34 |
|  | N + | 6 | 6 | 6 | 6 | 19 | 19 | 19 | 19 | 7 | 7 | 7 | 7 | 34 | 34 | 34 | 34 |
|  | N - | - | - | - | - | - | - | - | - | 1* | 1* | 1* | 1* | - | - | - | - |
|  | TP | 6 | 6 | 6 | 6 | 19 | 19 | 19 | 19 | 7 | 7 | 7 | 7 | 34 | 34 | 33 | 33 |
|  | FN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
|  | PPA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 97.06 | 97.06 |
|  | lower CI | 54.07 | 54.07 | 54.07 | 54.07 | 82.35 | 82.35 | 82.35 | 82.35 | 59.04 | 59.04 | 59.04 | 59.04 | 89.72 | 89.72 | 84.67 | 84.67 |

| Ig M | | upper CI | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 99.93 | 99.93 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ig | N | | 6 | 6 | 6 | 6 | 19 | 19 | 19 | 19 | 8 | 8 | 8 | 8 | 34 | 34 | 34 | 34 |
| M | N + | | 6 | 6 | 6 | 6 | 19 | 19 | 19 | 19 | 7 | 7 | 7 | 7 | 34 | 34 | 34 | 34 |
| | N - | | - | - | - | - | - | - | - | - | 1* | 1* | 1* | 1* | - | - | - | - |
| | TP | | 2 | 2 | 5 | 4 | 4 | 4 | 6 | 4 | 2 | 2 | 3 | 2 | 6 | 6 | 5 | 5 |
| | FN | | 4 | 4 | 1 | 2 | 15 | 15 | 13 | 15 | 5 | 5 | 4 | 5 | 28 | 28 | 29 | 29 |
| | PPA, % | | 33.33 | 33.33 | 83.33 | 66.67 | 21.05 | 21.05 | 31.58 | 21.05 | 28.57 | 28.57 | 42.86 | 28.57 | 17.65 | 17.65 | 14.71 | 14.71 |
| | | lower CI | 4.33 | 4.33 | 35.88 | 22.28 | 6.05 | 6.05 | 12.58 | 6.05 | 3.67 | 3.67 | 9.9 | 3.67 | 6.76 | 6.76 | 4.95 | 4.95 |
| | | upper CI | 77.72 | 77.72 | 99.58 | 95.67 | 45.57 | 45.57 | 56.55 | 45.57 | 70.96 | 70.96 | 81.59 | 70.96 | 34.53 | 34.53 | 31.06 | 31.06 |

*1 sample was detected as antibody-negative by the Elecsys Anti-SARS-CoV-2 S and the SARS-CoV-2 Rapid Antibody Test.

+, positive by the reference test (Elecsys Anti-SARS-CoV-2 S assay); -, negative by the reference test (Elecsys Anti-SARS-CoV-2

S assay); CI, 95% confidence intervals; TP, true-positive; FN, false-negative; PPA, positive percent agreement

Figure 1: SARS-CoV-2 Rapid Antibody Test semi-quantitative IgG vs Elecsys Anti-

SARS-CoV-2 S assay total antibody titer following vaccination with Moderna mRNA-

1273 or Pfizer-BioNTech BNT162b2 (at least 14 days following second dose)

Results from the SARS-CoV-2 Rapid Antibody Test were classified as negative or

one of the five levels of increasing positivity based upon line intensity (((+)), (+), +,

++ or +++). Maximum value attainable by the Elecsys Anti-SARS-CoV-2 assay was

>25,000 U/mL. Blue = Lot 1; red = Lot 2; ○ = Evaluator 1; + = Evaluator 2.

Figure 2: SARS-CoV-2 Rapid Antibody Test semi-quantitative IgM vs Elecsys Anti-

SARS-CoV-2 S assay total antibody titer following vaccination with Moderna mRNA-

1273 or Pfizer-BioNTech BNT162b2 (at least 14 days following second dose)

Results from the SARS-CoV-2 Rapid Antibody Test were classified as negative or

one of the five levels of increasing positivity based upon line intensity (((+)), (+), +,

++ or +++). Maximum value attainable by the Elecsys Anti-SARS-CoV-2 assay was

>25,000 U/mL. Blue = Lot 1; red = Lot 2; ○ = Evaluator 1; + = Evaluator 2.

Figure 3: Elecsys Anti-SARS-CoV-2 S assay total antibody titer over time following

vaccination with Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2 (second dose)

Maximum value attainable by the Elecsys Anti-SARS-CoV-2 assay was >25,000

U/mL. Blue = mRNA-1273; red = BNT162b2